SGHT
Sight Sciences, Inc. · Healthcare
Insiders bought $185K of Sight Sciences, Inc. in the last 12 months
1 insider bought on 2 days.
SGHT over the last year
Largest buyers, last 12 months
SGHT after insider buys
3 months after each buy, from the first price a copier could get.
10 buys since 2021 with 3 months of prices.
Every filing
47 insider filings since 2021, newest first
Brenton Taylor · EVP, Operations & R&D
Alison Bauerlein · Chief Operating Officer
James Rodberg · Chief Financial Officer
David Badawi · Chief Technology Officer
Paul Badawi · President and CEO
Jeremy B. Hayden · Chief Legal Officer
James Rodberg · Chief Financial Officer
David Badawi · Chief Technology Officer
Alison Bauerlein · Chief Operating Officer
Paul Badawi · President and CEO
Staffan Encrantz · Director
Alison Bauerlein · COO
Jeremy B. Hayden · General Counsel
Alison Bauerlein · COO
Paul Badawi · President, CEO and 10% owner
Paul Badawi · President, CEO and 10% owner
Jeremy B. Hayden · General Counsel
Paul Badawi · President, CEO and 10% owner
Jeremy B. Hayden · General Counsel
Alison Bauerlein · COO
Staffan Encrantz · Director and 10% owner
Jeremy B. Hayden · General Counsel
Staffan Encrantz · Director and 10% owner
Staffan Encrantz · Director and 10% owner
Staffan Encrantz · Director and 10% owner
Manohar K. Raheja · EVP, Research, Development
Staffan Encrantz · Director and 10% owner
Matthew Link · Chief Commercial Officer
Matthew Link · Chief Commercial Officer
Paul Badawi · President and CEO
Jeremy B. Hayden · General Counsel
Alison Bauerlein · CFO
Jeremy B. Hayden · General Counsel
Paul Badawi · President and CEO
Alison Bauerlein · CFO
Alison Bauerlein · CFO
Paul Badawi · President and CEO
Alison Bauerlein · CFO
Paul Badawi · President and CEO
Sam Boong Park · COO
D1 Capital Partners L.P. · 10% owner
Staffan Encrantz · Director and 10% owner
Staffan Encrantz · Director and 10% owner
Jesse Selnick · CFO
Staffan Encrantz · Director
Jesse Selnick · CFO
Staffan Encrantz · Director
About Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.